Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
1(33.3%)
Phase 1
1(33.3%)
Phase 2
1(33.3%)
3Total
N/A(1)
Phase 1(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT01961531Not ApplicableCompleted

BrUOG 291: Five Fraction Partial Breast Irradiation Using Non-invasive Image-guided Breast Brachytherapy (NIBB)

Role: collaborator

NCT00003406Phase 1Completed

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer

Role: lead

NCT00003408Phase 2Completed

Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer

Role: lead

All 3 trials loaded